Info

We are a biopharmaceutical company focused on the discovery, development and commercialization of small molecule therapeutics for the treatment of cardiovascular disorders. We believe our advanced understanding of the biology of cardiovascular disease combined with our clinical development expertise in cardiovascular therapeutics provide us with the capability to discover novel therapies, as well as identify, license, acquire and develop products that address serious, debilitating cardiovascular disorders that are not adequately treated with existing therapies. We have two selective oral endothelin receptor antagonist (ERA) product candidates in late-stage clinical development: ambrisentan which is in Phase 3 clinical development for the treatment of patients with pulmonary arterial hypertension (PAH) and darusentan which recently completed a Phase 2b clinical trial for the treatment of patients with resistant hypertension. Our product candidates are orally administered small molecules that may offer advantages over currently available therapies and address unmet needs in their respective markets. We also conduct a drug discovery research program in collaboration with the Novartis Institutes for BioMedical Research, Inc. (Novartis) through which we seek to discover and develop disease-modifying drugs for chronic heart failure and related disorders. Our goal is to create an integrated biopharmaceutical company focused on the discovery, development and commercialization of novel therapies that address the fundamental mechanisms involved in cardiovascular disease, with an initial focus on highly debilitating chronic conditions. Our strategy is to utilize our advanced understanding of the molecular biology and clinical medicine of cardiovascular disease to (i) complete the clinical development of, and obtain regulatory approvals for, ambrisentan and darusentan, (ii) discover and develop novel therapeutics which slow or reverse the progression of cardiovascular disease, and (iii) identify and acquire additional clinical-stage compounds. In addition, we plan to develop our own sales and marketing capabilities focused on targeted markets and to enter into co-promotion or licensing partnerships with larger pharmaceutical or biotechnology companies when necessary to reach larger markets. Similarly, we intend to selectively enter into strategic research and development collaborations with other pharmaceutical or biotechnology companies to advance our research program.